ScholarMate
English简体中文繁體中文
客服热线:400-1616-289
登录注册
期刊论文

An integrated RNA sequencing and network pharmacology approach reveals the molecular mechanism of dapagliflozin in the treatment of diabetic nephropathy

Bai, Zhenyu; Xie, Ting; Liu, Tianhao; Chen, Zedong; Yu, Linde; Zhang, Chao; Luo, Jincheng; Chen, Liguo*; Zhao, Xiaoshan*; Xiao, Ya*南方医科大学; 江南大学; y
Frontiers in Endocrinology2022-9-21DOI: 10.3389/fendo.2022.967822
2被引23阅读
引用收藏
分享

摘要

Dapagliflozin, an inhibitor of sodium-glucose cotransporter 2 (SGLT2), is a new type of oral hypoglycemic drugs which can promote glucose excretion in the kidney. Studies have shown that dapagliflozin has renoprotective effect in the treatment of type 2 diabetes. However, the underlying mechanism remains unclear. Here, we combined integrated RNA sequencing and network pharmacology approach to investigate the molecular mechanism of dapagliflozin for diabetic nephropathy (DN). Dapagliflozin significantly relieved glucose intolerance, urinary albumin/creatinine ratio (UACR) and renal pathological injuries of db/db mice. The LncRNA and mRNA expression in kidney tissues from control group (CR), db/db group (DN) and dapagliflozin group (DG) were assessed by RNA sequencing. We identified 7 LncRNAs and 64 mRNAs common differentially expressed in CR vs DN and DN vs DG, which were used to construct co-expression network to reveal significantly correlated expression patterns in DN. In addition, network pharmacology was used to predict the therapeutic targets of dapagliflozin and we constructed component-target-pathway network according to the results of RNA sequencing and network pharmacology. We found that SMAD9, PPARG, CD36, CYP4A12A, CYP4A12B, CASP3, H2-DMB2, MAPK1, MAPK3, C3 and IL-10 might be the pivotal targets of dapagliflozin for treating DN and these genes were mainly enriched in pathways including TGF-beta signaling pathway, PPAR signaling pathway, Chemokine signaling pathway, etc. Our results have important implication and provide novel insights into the protective mechanism of dapagliflozin for treating DN.

学科与关键词

关键词
diabetic nephropathydapagliflozinRNA sequencingnetwork pharmacologysodium-glucose cotransporter 2
相关
加载中…

文献加载失败,请重试

重试

发表信息

论文状态
公开发表
期刊
Frontiers in Endocrinology
发表日期
2022-09-21
卷期
第 13 卷
页码
967822
DOI
10.3389/fendo.2022.967822
期刊等级
3区
成果收录
SCIE
资助标注
National Natural Science Foundation of China; Natural Science Foundation of Guangdong Province, China; Wuxi Municipal Health Commission Scientific Research Fund Youth Project; [82074307]; [82174148]; [2018030310451]; [Q202106]

作者

  • B

    Bai, Zhenyu (第一作者)

  • X

    Xie, Ting

查看全部 10 位作者收起作者
  • L

    Liu, Tianhao

    jiangnan univ

  • C

    Chen, Zedong

  • Y

    Yu, Linde

  • Z

    Zhang, Chao

  • L

    Luo, Jincheng

  • C

    Chen, Liguo (通讯)

  • Z

    Zhao, Xiaoshan (通讯)

    southern med univ

  • X

    Xiao, Ya (通讯)

登录解锁更多功能

  • 收藏这篇,随时在“我的 · 收藏”找回
  • 认领你的成果,生成推广素材
  • 关注作者获取最新成果
  • 加入项目组、协同写作
注册 / 登录

产品服务

  • 科研之友
  • 创新城
  • 科创云

服务支持

  • 帮助中心
  • 隐私政策
  • 服务条款

联系方式

在线客服:【】
客服热线:400-1616-289
电子邮箱:support@scholarmate.com

关注或下载科研之友

微信二维码
微信公众号
客户端下载二维码
下载客户端
科研成果科研人员科研机构科研动态爱瑞思软件

©2026 深圳市科研之友网络服务有限公司

公安备案图标粤公网安备 44030502000213
粤ICP备 16046710 号粤B2-20110417